Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: Results of a meta-analysis

Breast Cancer Research and Treatment

Volumn 122, Issue 3, 2010, Pages 609-617

  Seruga, Bostjan ^a   Amir, Eitan ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adjuvant; Cytochrome P450 2D6; Drug inhibitors; Genotype; Survival; Tamoxifen

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 2D6 INHIBITOR; OXIDOREDUCTASE INHIBITOR; PAROXETINE; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ENZYME INHIBITOR;

BREAST CANCER; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG SENSITIVITY; EVENT FREE SURVIVAL; GENETIC HETEROGENEITY; GENOTYPE; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; ENZYMOLOGY; FEMALE; PHYSIOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYTOCHROME P-450 CYP2D6; ENZYME INHIBITORS; FEMALE; HUMANS; TAMOXIFEN; TREATMENT OUTCOME; CYTOCHROME P-450 CYP2D6 INHIBITORS;

EID: 77955556907     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0902-3     Document Type: Review

References (43)

1. SS Dehal D Kupfer 1997 CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver Cancer Res 57 3402 3406 1:CAS:528:DyaK2sXls1Shurw%3D 9270005
2. Z Desta BA Ward NV Soukhova DA Flockhart 2004 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6 J Pharmacol Exp Ther 310 1062 1075 10.1124/jpet.104.065607 1:CAS:528:DC%2BD2cXnt1eqtb0%3D 15159443 (Pubitemid 39108928)
3. MD Johnson H Zuo KH Lee JP Trebley JM Rae RV Weatherman Z Desta DA Flockhart TC Skaar 2004 Pharmacological characterization of 4-hydroxy-N- desmethyl tamoxifen, a novel active metabolite of tamoxifen Breast Cancer Res Treat 85 151 159 10.1023/B:BREA.0000025406.31193.e8 1:CAS:528: DC%2BD2cXjsVertbc%3D 15111773 (Pubitemid 38987269)
4. YC Lim L Li Z Desta Q Zhao JM Rae DA Flockhart TC Skaar 2006 Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells J Pharmacol Exp Ther 318 503 512 10.1124/jpet.105.100511 1:CAS:528:DC%2BD28XnslOls7o%3D 16690721 (Pubitemid 44061223)
5. XL Wu JR Hawse M Subramaniam MP Goetz JN Ingle TC Spelsberg 2009 The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells Cancer Res 69 1722 1727 10.1158/0008-5472.CAN-08-3933 1:CAS:528:DC%2BD1MXisFSrtr8%3D 19244106
6. V Stearns MD Johnson JM Rae A Morocho A Novielli P Bhargava DF Hayes Z Desta DA Flockhart 2003 Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine J Natl Cancer Inst 95 1758 1764 1:CAS:528:DC%2BD3sXpvVelsbc%3D 14652237
7. M Ingelman-Sundberg SC Sim A Gomez C Rodriguez-Antona 2007 Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects Pharmacol Ther 116 496 526 10.1016/j.pharmthera.2007.09.004 1:CAS:528:DC%2BD2sXhtlCrs7bE 18001838 (Pubitemid 350116943)
8. LD Bradford 2002 CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants Pharmacogenomics 3 229 243 10.1517/14622416.3.2. 229 1:CAS:528:DC%2BD38XitlWqu70%3D 11972444 (Pubitemid 34223859)
9. Y Jin Z Desta V Stearns B Ward H Ho KH Lee T Skaar AM Storniolo L Li A Araba R Blanchard A Nguyen L Ullmer J Hayden S Lemler RM Weinshilboum JM Rae DF Hayes DA Flockhart 2005 CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 30 39 10.1093/jnci/dji005 1:CAS:528:DC%2BD2MXisVaqsw%3D%3D 15632378
10. HS Lim LH Ju LK Seok LE Sook IJ Jang J Ro 2007 Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer J Clin Oncol 25 3837 3845 10.1200/JCO.2007.11.4850 1:CAS:528: DC%2BD2sXhtFanu7zK 17761971 (Pubitemid 47477258)
11. MP Goetz JM Rae VJ Suman SL Safgren MM Ames DW Visscher C Reynolds FJ Couch WL Lingle DA Flockhart Z Desta EA Perez JN Ingle 2005 Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes J Clin Oncol 23 9312 9318 10.1200/JCO.2005.03.3266 1:CAS:528:DC%2BD28Xnt1ynuw%3D%3D 16361630
12. K Kiyotani T Mushiroda CK Imamura N Hosono T Tsunoda M Kubo Y Tanigawara DA Flockhart Z Desta TC Skaar F Aki K Hirata Y Takatsuka M Okazaki S Ohsumi T Yamakawa M Sasa Y Nakamura H Zembutsu 2010 Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients J Clin Oncol 28 1287 1293 10.1200/JCO.2009.25.7246 1:CAS:528:DC%2BC3cXksFSqtb0%3D 20124171
13. W Schroth MP Goetz U Hamann PA Fasching M Schmidt S Winter P Fritz W Simon VJ Suman MM Ames SL Safgren MJ Kuffel HU Ulmer J Bolander R Strick MW Beckmann H Koelbl RM Weinshilboum JN Ingle M Eichelbaum M Schwab H Brauch 2009 Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen JAMA 302 1429 1436 10.1001/jama.2009.1420 1:CAS:528:DC%2BD1MXht1CksrjO 19809024
14. Y Xu Y Sun L Yao L Shi Y Wu T Ouyang J Li T Wang Z Fan T Fan B Lin L He P Li Y Xie 2008 Association between CYP2D6 10 genotype and survival of breast cancer patients receiving tamoxifen treatment Ann Oncol 19 1423 1429 10.1093/annonc/mdn155 1:STN:280:DC%2BD1cvotVKmsA%3D%3D 18407954
15. SA Nowell JY Ahn JM Rae JO Scheys A Trovato C Sweeney SL MacLeod FF Kadlubar CB Ambrosone 2005 Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients Breast Cancer Res Treat 91 249 258 10.1007/s10549-004-7751-x 1:CAS:528:DC%2BD2MXltFGqsLs%3D 15952058 (Pubitemid 40903087)
16. W Schroth L Antoniadou P Fritz M Schwab T Muerdter UM Zanger W Simon M Eichelbaum H Brauch 2007 Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes J Clin Oncol 25 5187 5193 10.1200/JCO.2007.12.2705 1:CAS:528:DC%2BD2sXhsVKnsbzN 18024866 (Pubitemid 350232249)
17. P Wegman S Elingarami J Carstensen O Stal B Nordenskjold S Wingren 2007 Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer Breast Cancer Res 9 R7 10.1186/bcr1640 17244352 (Pubitemid 350215154)
18. RE Aubert EJ Stanek J Yao JR Teagarden M Subar RS Epstein TC Skaar Z Desta DA Flockhart 2009 Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors J Clin Oncol (Meeting Abstracts) 27 CRA508
19. V Dezentje NJ Van Blijderveen H Gelderblom H Putter MP Van Herk-Sukel MK Casparie AC Egberts JW Nortier HJ Guchelaar 2009 Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: a pharmacoepidemiologic study J Clin Oncol (Meeting Abstracts) 27 CRA509
20. CM Kelly DN Juurlink T Gomes M Duong-Hua KI Pritchard PC Austin LF Paszat 2010 Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study BMJ 340 c693 10.1136/bmj.c693 20142325
21. RP Harris M Helfand SH Woolf KN Lohr CD Mulrow SM Teutsch D Atkins 2001 Current methods of the US Preventive Services Task Force: a review of the process Am J Prev Med 20 21 35 10.1016/S0749-3797(01)00261-6 1:STN:280:DC%2BD38%2FgvVWquw%3D%3D 11306229
22. Deeks JJ, Higgins, JPT, Altman DG (eds) (2006) Analysing and presenting results. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. In: The Cochrane Library, Chichester, UK, John Wiley & Sons, Ltd
23. R DerSimonian N Laird 1986 Meta-analysis in clinical trials Control Clin Trials 7 177 188 10.1016/0197-2456(86)90046-2 1:STN:280:DyaL2s7gsVamtA%3D%3D 3802833 (Pubitemid 17189972)
24. S Gonzalez-Santiago R Zarate J Haba-Rodriguez A Gomez E Bandres P Borrega J Garcia-Foncillas E Aranda 2006 Genetic polymorphism CYP2D6(4) interaction in clinical outcomes of tamoxifen-treated breast cancer patients Ann Oncol 17 62 63 10.1093/annonc/mdj952 (Pubitemid 43985207)
25. MP Goetz SK Knox VJ Suman JM Rae SL Safgren MM Ames DW Visscher C Reynolds FJ Couch WL Lingle RM Weinshilboum EG Fritcher AM Nibbe Z Desta A Nguyen DA Flockhart EA Perez JN Ingle 2007 The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen Breast Cancer Res Treat 101 113 121 10.1007/s10549-006-9428-0 1:CAS:528:DC%2BD2sXisVylsg%3D%3D 17115111 (Pubitemid 47555336)
26. WG Newman KD Hadfield A Latif SA Roberts A Shenton C McHague F Lalloo S Howell DG Evans 2008 Impaired tamoxifen metabolism reduces survival in familial breast cancer patients Clin Cancer Res 14 5913 5918 10.1158/1078-0432.CCR-07- 5235 1:CAS:528:DC%2BD1cXhtFaitrjF 18794105
27. MP Goetz DA Berry TE Klein 2009 Adjuvant tamoxifen treatment outcome according to cytochrome P450 2D6 (CYP2D6) phenotype in early stage breast cancer: findings from the International Tamoxifen Pharmacogenomics Consortium Cancer Res 69 492S 493S 10.1158/0008-5472.CAN-08-2962
28. Thompson A, Quinlan P, Bray S, Johnson A, Nikoloff M, Fontecha M, Ferraldeschi R, Howell A, Lawrence J, Newman W (2009) CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy. In: Proc Am Soc Clin Oncol Breast Cancer Symposium, Abstract 35.
29. M Okishiro T Taguchi SJ Kim K Shimazu Y Tamaki S Noguchi 2009 Genetic polymorphisms of CYP2D610 and CYP2C192,3 are not associated with prognosis, endometrial thickness, or bone mineral density in japanese breast cancer patients treated with adjuvant tamoxifen Cancer 115 952 961 10.1002/cncr.24111 1:CAS:528:DC%2BD1MXjs1Kjur0%3D 19156902
30. K Kiyotani T Mushiroda M Sasa Y Bando I Sumitomo N Hosono M Kubo Y Nakamura H Zembutsu 2008 Impact of CYP2D610 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy Cancer Sci 99 995 999 10.1111/j.1349-7006.2008.00780.x 1:CAS:528:DC%2BD1cXlslCrtrc%3D 18294285 (Pubitemid 351997603)
31. JE Abraham M Maranian K Driver D Greenberg MN Shah HM Earl AM Dunning PPDP Pharoah C Caldas 2009 Cytochrome P450 2D6 variants and their association with breast cancer survival Cancer Res 69 229S
32. P Wegman L Vainikka O Stal B Nordenskjold L Skoog LE Rutqvist S Wingren 2005 Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients Breast Cancer Res 7 R284 R290 10.1186/bcr993 1:CAS:528:DC%2BD2MXitF2qtr0%3D 15987423
33. T Toyama H Yamashita H Sugiura N Kondo H Iwase Y Fujii 2009 No association between CYP2D6 10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment Jpn J Clin Oncol 39 651 656 10.1093/jjco/hyp076 19596663
34. T Ramon y Cajal A Altes L Pare E del Rio C Alonso A Barnadas M Baiget 2010 Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment Breast Cancer Res Treat 119 33 38 10.1007/s10549-009-0328-y 1:CAS:528:DC%2BD1MXhsFaqtrzL 19189210
35. MJ Bijl RHN van Schaik LA Lammers A Hofman AG Vulto T van Gelder BHC Stricker LE Visser 2009 The CYP2D64 polymorphism affects breast cancer survival in tamoxifen users Breast Cancer Res Treat 118 125 130 10.1007/s10549-008-0272-2 1:CAS:528:DC%2BD1MXht1GmtbbI 19189212
36. JM Rae J Thibert MJ Sikora MD Johnson A Skene R A'Hern IE Smith M Dowsett 2009 Lack of correlation between genetic polymorphisms in tamoxifen metabolizing enzymes with primary endpoints in the IMPACT trial Cancer Res 69 595S 596S
37. TL Lash D Cronin-Fenton TP Ahern CL Rosenberg KL Lunetta RA Silliman S Hamilton-Dutoit JP Garne M Ewertz HT Sorensen L Pedersen 2010 Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen Acta Oncol 49 305 312 10.3109/02841860903575273 1:CAS:528:DC%2BC3cXkvVagu7k%3D 20156115
38. -(1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351:1451-1467
39. A Decensi C Robertson G Viale F Pigatto H Johansson ER Kisanga P Veronesi R Torrisi M Cazzaniga S Mora MT Sandri G Pelosi A Luini A Goldhirsch EA Lien U Veronesi 2003 A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers J Natl Cancer Inst 95 779 790 10.1093/jnci/95.11.779 1:CAS:528:DC%2BD3sXksVWqtr8%3D 12783932
40. JF Forbes J Cuzick A Buzdar A Howell JS Tobias M Baum 2008 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 9 45 53 10.1016/S1470-2045(07) 70385-6 18083636
41. H Mouridsen A Giobbie-Hurder A Goldhirsch B Thurlimann R Paridaens I Smith L Mauriac JF Forbes KN Price MM Regan RD Gelber AS Coates 2009 Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer N Engl J Med 361 766 776 10.1056/NEJMoa0810818 1:CAS:528:DC%2BD1MXhtVWls7fM 19692688
42. RS Punglia HJ Burstein EP Winer JC Weeks 2008 Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis J Natl Cancer Inst 100 642 648 10.1093/jnci/djn100 1:CAS:528:DC%2BD1cXlslymtbc%3D 18445827
43. HN Lynn JM Rae L Li F Azzouz TC Skaar Z Desta MJ Sikora S Philips AT Nguyen AM Storniolo DF Hayes DA Flockhart V Stearns 2009 Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort Breast Cancer Res Treat 117 571 575 10.1007/s10549-009-0309-1